CVS Health
CVS
$95.99
+0.10%
CVS Health Corporation is a diversified healthcare services company operating in the Medical - Healthcare Plans industry, integrating retail pharmacy, pharmacy benefit management (PBM), and health insurance (via Aetna) under one roof. It is a dominant, vertically integrated player in the U.S. healthcare landscape, distinct for its 'one-stop-shop' model that aims to control costs and improve patient outcomes across the care continuum. The current investor narrative is driven by a significant positive catalyst from a favorable Medicare Advantage payment update, which has improved revenue visibility and profit outlooks, alongside ongoing debates about the execution and synergy realization from its integrated model and recent acquisitions like Oak Street Health.…
CVS
CVS Health
$95.99
Related headlines
CVS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $124.79 and implied upside of +30.0% versus the current price.
Average Target
$124.79
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$77 - $125
Analyst target range
The stock is covered by 13 analysts, indicating substantial institutional interest. The consensus sentiment is bullish, with recent actions including an upgrade from Bernstein to 'Outperform' in March 2026 and maintained 'Buy' or 'Overweight' ratings from firms like B of A Securities, JP Morgan, UBS, and Mizuho. The average target price is not explicitly provided in the data, but the implied upside or downside cannot be calculated without it; however, the pattern of recent upgrades and positive commentary suggests analysts see further room for appreciation. The target price range is also not specified in the provided dataset. The wide dispersion in recent quarterly earnings and the major regulatory catalyst (Medicare payments) likely contribute to a broader range of analyst assumptions. The recent upgrade cycle, particularly Bernstein's move from 'Market Perform' to 'Outperform', signals strengthening conviction following the positive fundamental developments, which should lead to target price increases and reinforce the bullish narrative.
Bulls vs Bears: CVS Investment Factors
The bull case currently holds stronger evidence, driven by a powerful, concrete catalyst (the $13B Medicare payment update) and strong underlying fundamentals like 8.17% revenue growth and a 7.8% FCF yield. The bear case is grounded in legitimate concerns about earnings volatility and thin margins, but these are structural and known characteristics of the business model. The single most important tension in the investment debate is whether the company can translate its recent regulatory windfall and massive scale into sustained, less volatile profitability through successful integration. If CVS can demonstrate consistent margin improvement and earnings stability in upcoming quarters, the stock could re-rate higher. If execution stumbles and earnings remain erratic, the recent rally could reverse as the market loses patience.
Bullish
- Major Medicare Payment Catalyst: A favorable 2027 Medicare Advantage payment update from CMS has provided a significant $13 billion revenue reprieve, directly improving the profit outlook for CVS's Aetna segment. This regulatory tailwind is the primary driver behind the stock's 27.87% surge over the past month and has led to analyst upgrades, including Bernstein's move to 'Outperform'.
- Strong Revenue Growth & Scale: Q4 2025 revenue grew 8.17% year-over-year to $105.69 billion, with accelerating multi-quarter trends. This demonstrates the power of its vertically integrated model, with Pharmacy ($61.62B) and Premiums ($34.02B) segments both contributing significantly, providing a massive and diversified revenue base.
- Exceptional Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $7.81 billion, representing a 7.8% FCF yield based on its market cap. This strong cash generation provides ample liquidity to fund dividends, reduce its manageable 1.24x debt-to-equity ratio, and invest in growth initiatives like Oak Street Health integration.
- Attractive Forward Valuation: Despite a high trailing P/E of 56.87x (distorted by volatile earnings), the forward P/E of 11.47x is reasonable and sits within its historical range. The stock trades at a significant discount on sales multiples (P/S of 0.25x, EV/Sales of 0.47x), typical for the sector but offering value relative to its integrated scale.
Bearish
- Extreme Earnings Volatility: Profitability is highly inconsistent, with Q4 2025 net income of $2.94 billion swinging from a massive $3.98 billion loss in Q3 2025. This volatility, driven by factors like medical cost ratios and integration charges, makes future earnings difficult to predict and undermines the reliability of the trailing P/E metric.
- Very Low Operating Margins: The company operates on razor-thin margins, with a Q4 2025 operating margin of just 2.58% and a gross margin of 12.84%. This highlights the low-margin nature of its pharmacy and insurance businesses, leaving little room for error and requiring massive scale to generate meaningful profits.
- Extended Near-Term Price & Valuation: Trading at 97.4% of its 52-week high after a 27.87% monthly surge, the stock is technically extended and may be due for consolidation. The trailing P/E of 56.87x, while distorted, is near the top of its historical range, suggesting near-term optimism may be fully priced in pending execution.
- Integration & Execution Risk: The success of the investment thesis hinges on realizing synergies from its vertically integrated model and recent acquisitions like Oak Street Health. Failure to execute on cost control, cross-selling, and improving patient outcomes could stall growth and compress the valuation premium for the 'one-stop-shop' narrative.
CVS Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 58.57% gain over the past year. As of the latest close at $95.89, CVS is trading at approximately 97.4% of its 52-week high of $98.43, positioning it near the peak of its annual range. This proximity to highs reflects strong bullish momentum but also suggests the stock may be extended in the near term, warranting caution for new entries. Recent momentum has been exceptionally strong, with the stock surging 27.87% over the past month and 22.18% over the past three months, significantly outpacing the S&P 500's respective gains of 5.6% and 8.42%. This explosive short-term acceleration, diverging from a longer-term uptrend, is a clear signal of a powerful bullish breakout, likely driven by fundamental catalysts like the improved Medicare outlook. Key technical support is anchored at the 52-week low of $58.50, while immediate resistance is at the 52-week high of $98.43. A decisive breakout above $98.43 would signal a continuation of the uptrend, while a failure could lead to consolidation. With a beta of 0.592, CVS exhibits approximately 41% less volatility than the broader market, which is notable given its recent surge and suggests its moves, while large, are fundamentally driven rather than speculative.
Beta
0.59
0.59x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$59-$98
Price range past year
Annual Return
+53.5%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | +24.2% | +4.0% |
| 3m | +22.7% | +8.2% |
| 6m | +25.4% | +11.5% |
| 1y | +53.5% | +24.3% |
| ytd | +19.8% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue growth is solid, with Q4 2025 revenue of $105.69 billion representing an 8.17% year-over-year increase. Segment data reveals Pharmacy Revenue ($61.62B) and Premiums ($34.02B) as the primary drivers, indicating strength in both the PBM and insurance segments. The multi-quarter trend shows revenue growth accelerating from the prior year, supporting a positive investment case centered on scale and integration. Profitability is present but exhibits volatility; Q4 2025 net income was a strong $2.94 billion, rebounding from a significant loss of -$3.98 billion in Q3 2025. The gross margin for the quarter was 12.84%, which is low but typical for a high-volume, low-margin business model like pharmacy and managed care. The operating margin was 2.58%, indicating the company converts a small portion of its massive revenue into operating profit, a key area for potential improvement through integration. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.24, which is manageable for a company of its size and cash flow profile. Financial health is supported by robust cash generation, with trailing twelve-month free cash flow of $7.81 billion and a current ratio of 0.84. The strong FCF, which yields approximately 7.8% based on market cap, provides ample liquidity to fund operations, pay dividends, and reduce debt, mitigating financial risk.
Quarterly Revenue
$105.7B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.12%
Latest Quarter
Free Cash Flow
$7.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 56.87x, largely distorted by the volatile quarterly earnings, including a significant loss in Q3 2025. The forward PE is a much more reasonable 11.47x, indicating the market expects a substantial normalization and growth in earnings over the next twelve months. Compared to industry averages, CVS trades at a significant discount on a sales basis, with a Price-to-Sales ratio of 0.25x and an EV-to-Sales of 0.47x; these low multiples are characteristic of low-margin, high-revenue businesses in the managed care and pharmacy sectors. The forward PE of ~11.5x is also generally in line with or below many healthcare services peers, suggesting the stock is not overvalued relative to the sector despite its recent run. Historically, the stock's current trailing PE of 56.87x is near the top of its own range over the past several years, as seen in historical data where it has typically fluctuated between single digits and the low 20s. This elevated level is an artifact of depressed trailing earnings rather than excessive optimism, and the more informative forward PE of 11.47x sits comfortably within its historical band, suggesting the market is pricing in a recovery to normalized profitability levels.
PE
56.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -9x~227x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CVS faces significant earnings volatility, as evidenced by the swing from a $3.98 billion loss in Q3 2025 to a $2.94 billion profit in Q4 2025. This makes forecasting challenging. The business model inherently carries low profitability, with operating margins of just 2.58%, leaving minimal buffer against cost pressures. Furthermore, the company's current ratio of 0.84 indicates a tight liquidity position relative to short-term obligations, though this is substantially mitigated by its robust $7.81 billion annual free cash flow generation.
Market & Competitive Risks: The stock's recent 58.57% run-up positions it near its 52-week high, increasing near-term valuation compression risk if growth expectations are not met. While its forward P/E of 11.47x appears reasonable, the sector faces persistent regulatory scrutiny and political pressure on healthcare costs, which could impact future pricing power for its PBM and insurance segments. Its low beta of 0.592 suggests it is less sensitive to broad market swings, but it remains exposed to sector-specific rotations out of healthcare services if sentiment sours.
Worst-Case Scenario: The most damaging scenario would involve a failure to realize integration synergies coinciding with a regulatory reversal on Medicare payments and a spike in medical costs, leading to a return of severe quarterly losses. This could trigger multiple compression and a loss of investor confidence in the integrated model. A realistic downside could see the stock retreat towards its 52-week low of $58.50, representing a potential loss of approximately -39% from the current price of $95.89. The recent max drawdown of -16.44% from the January 2026 peak shows the stock is not immune to sharp corrections.
